JQJuan Eduardo Quiroz-Aldave

Juan Eduardo Quiroz-Aldave

*This is an algorithmically generated author record based on publicly available information.

Juan Eduardo Quiroz-Aldave has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk

    by Marcio J. Concepcion-Zavaleta, Jenyfer M. Fuentes-Mendoza, Luis Concepción-Urteaga, Selina A. Castillo-Balderas, Juan Carlos Morón Siguas, José Paz-Ibarra, Juan Eduardo Quiroz Aldave

    Prediabetic neuropathy is increasingly recognized as an early consequence of glucose dysregulation that may precede type 2 diabetes and contribute to cardiovascular risk. This narrative review summarizes current evidence on autonomic dysfunction in prediabetes, including its epidemiology, pathophysiology, clinical significance, and therapeutic implications. A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science for studies published between 2010 and 2026. Evidence indicates that alterations in heart rate variability, impaired baroreflex sensitivity, endothelial dysfunction, and chronic low-grade inflammation contribute to autonomic imbalance and increased cardiovascular risk in individuals with impaired fasting glucose or impaired glucose tolerance. Autonomic dysfunction should be considered an early manifestation of cardiometabolic disease rather than a late complication of diabetes. Although accumulating evidence supports its prognostic relevance, routine screening remains limited by the absence of standardized diagnostic criteria and clear guideline recommendations. Incorporating autonomic assessment into risk stratification may facilitate earlier identification of high-risk individuals and support targeted preventive strategies. Future studies should focus on validating diagnostic thresholds and determining whether early intervention improves long-term cardiovascular outcomes.

  • Skin as a mirror of endocrine diseases: emerging biomarkers and targeted therapies

    by Jenyfer M. Fuentes-Mendoza, Marcio J. Concepción-Zavaleta, Jean Pierre Villanueva-De La Cruz, Arturo Basurto-Ayala, Pepita Albarracin-Lescano, Juan Quiroz-Aldave, Luis Concepción-Urteaga, José Paz-Ibarra

    Several metabolic and endocrine disregulations often result in clinically significant dermatological lesions, ranging from common findings such as acanthosis nigricans (AN) and hyperpigmentation to...

  • Neutrophil-to-lymphocyte ratio as a risk factor for prolonged hospital stay in stroke: The Peru-Casimiro study

    by Milagros del Rosario Xiomi Rojas-Catacora, Marcio José Concepción-Zavaleta, Jenyfer María Fuentes-Mendoza, Miguel A. Vences, Julia Coronado-Arroyo, Ruth Elena Catacora Hilasaca, Luis Concepción-Urteaga, Juan Eduardo Quiroz-Aldave, Cristian David Armas-Flórez

    The neutrophil-to-lymphocyte ratio (NLR) is an accessible biomarker of systemic inflammation with potential prognostic utility in cerebrovascular disease (CVD). Its relationship with prolonged hospitalization in stroke remains insufficiently explored in Peruvian populations. To evaluate whether the NLR at admission is associated with prolonged hospital stay (≥ 9 days) in patients with ischemic and hemorrhagic CVD treated at Hospital de Emergencias José Casimiro Ulloa (2022-2024) METHODS: A retrospective observational study was performed including 227 adults with confirmed CVD. Clinical, demographic, and laboratory data were retrieved from medical records. Optimal NLR cut-offs were determined using RO1C curve analysis. Logistic regression models-stratified by stroke subtype-assessed associations between NLR and prolonged hospitalization, adjusting for relevant clinical variables and collinearity. Among 227 patients, 61.7% had ischemic and 38.3% hemorrhagic CVD. Prolonged stay occurred in 21.4% of ischemic and 54.0% of hemorrhagic cases. ROC analysis identified optimal NLR cut-offs of 3.16 (ischemic; AUC = 0.738) and 3.18 (hemorrhagic; AUC = 0.616). In ischemic CVD, NLR was the only independent predictor of prolonged stay (adjusted OR = 1.173; p = 0.005). No variable, including NLR, independently predicted prolonged hospitalization in hemorrhagic CVD. Admission NLR may be an independent predictor of prolonged hospital stay in ischemic but not hemorrhagic stroke. NLR may support early risk stratification in resource-limited emergency settings. Prospective studies incorporating standardized stroke severity measures are needed.

  • Endocrine Disorders and Psychiatric Symptoms: A Comprehensive Overview

    by Marcio J. Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Jenyfer M. Fuentes-Mendoza, María del Carmen Durand-Vásquez, Arturo Basurto-Ayala, Luis Concepción-Urteaga, Danitza Cárdenas Peralta, José Paz-Ibarra

  • Endocrine hypertension in 2025: how AI and multiomics are revolutionizing detection

    by Jenyfer M. Fuentes-Mendoza, Marcio J. Concepción-Zavaleta, Jeny J. Mendoza-Godoy, Juan Eduardo Quiroz-Aldave, Juan Carlos Morón-Siguas, José L. Paz-Ibarra

    Endocrine hypertension (EH) represents a small yet clinically significant subset of secondary hypertension with curative potential. Recent advances in multiomics and artificial intelligence (AI) are transforming the diagnostic and therapeutic paradigms of EH, enabling earlier detection, precise subtyping, and personalized treatment strategies. This review integrates evidence from PubMed, Scopus, and Web of Science (2000-July 2025) addressing the role of genomics, transcriptomics, proteomics, and metabolomics combined with AI in the diagnosis and management of EH, including primary aldosteronism, Cushing's syndrome, pheochromocytoma/paraganglioma, and thyroid-related hypertension. It highlights the shift toward molecularly informed clinical pathways, noninvasive biomarkers, and predictive algorithms for subtype differentiation and therapeutic optimization. The convergence of multiomics and AI heralds a transformative era in EH care. While proof-of-concept studies demonstrate diagnostic accuracy comparable to invasive tests, translation into routine practice is limited by infrastructural inequities, lack of data harmonization, and gaps in clinician digital literacy. Future efforts should prioritize federated data systems, longitudinal multiomic integration, and hybrid models of human - machine collaboration. Within a decade, endocrine hypertension management will likely evolve from static, phenotype-based diagnosis to dynamic, data-driven systems medicine, integrating continuous biosensing and AI-guided decision support for truly individualized care.

  • Optimising contraceptive counselling: insights for obesity and bariatric surgery patients

    by Julia C. Coronado-Arroyo, Jenyfer María Fuentes-Mendoza, Marcio Concepción-Zavaleta, Fernanda Ginebra Castillo-Velásquez, Diego Velarde-García, Juan Eduardo Quiroz-Aldave, Luis Concepción-Urteaga, José Paz-Ibarra

    Women with obesity and those undergoing bariatric surgery face unique challenges when selecting contraceptive methods due to metabolic alterations, surgical malabsorption, and increased thromboembolic risk. This narrative review aims to summarise current evidence and provide practical guidance for safe and effective contraceptive counselling in these populations. A comprehensive narrative search was conducted in PubMed, Scopus and Google Scholar up to May 2025 using terms related to 'contraception', 'obesity', and 'bariatric surgery'. Recent international guidelines and clinical studies were synthesised to identify evidence-based recommendations and knowledge gaps. Combined hormonal contraceptives are relatively contraindicated in women with obesity, particularly in those with additional cardiovascular risk factors. Long-acting reversible contraception (LARC) methods, including intrauterine devices and subdermal implants, demonstrate the highest safety and effectiveness. Progestogen-only methods may be appropriate alternatives, while oral routes are less reliable after malabsorptive procedures. Tailored contraceptive counselling is essential for women with obesity and post-bariatric surgery. Prioritising LARC options, assessing individual thrombotic and metabolic risk, and providing multidisciplinary follow-up can optimise reproductive health outcomes in this growing population.

  • Open Access

    Papillary thyroid carcinoma in thyroglossal duct cyst: a Peruvian case series

    by José Luis Paz-Ibarra, Marialejandra Delgado Rojas, Edward Paucar Holgado, Jenyfer María Fuentes-Mendoza, Luis Concepción-Urteaga, Juan Eduardo Quiroz-Aldave, Marcio José Concepción-Zavaleta, José Somocurcio Peralta

    Summary: Papillary thyroid carcinoma (PTC) is the most frequent type of differentiated thyroid cancer, while thyroglossal duct cysts (TGDCs) are common congenital anomalies of the neck. The coexistence of PTC within a TGDC is exceptionally rare, with a reported incidence of less than 1.5%. We present three Peruvian cases of PTC arising in TGDCs. The patients (two females and one male; age range: 34–47 years) presented with progressive midline cervical masses of two to four years’ duration. All underwent cervical ultrasound, contrast-enhanced computed tomography, and fine-needle aspiration biopsy. Histopathology confirmed PTC, including classical and follicular variants. Surgical management varied: two patients underwent Sistrunk procedure alone, while one required Sistrunk surgery followed by total thyroidectomy, cervical lymph node dissection, and radioactive iodine (RAI) therapy. All patients remain disease-free after 6–12 years of follow-up. The diagnosis of carcinoma in TGDC is often incidental, but preoperative imaging and cytology can raise suspicion. Optimal management remains controversial; while the Sistrunk procedure may be sufficient in most cases of PTC confined to TGDC without extracapsular extension, in some scenarios, such as the presence of suspicious thyroid nodules, extracystic extension, and cervical lymph node metastasis, an additional thyroidectomy and RAI therapy may be warranted. In conclusion, PTC in TGDC is a rare entity with generally favorable prognosis. Early recognition, individualized treatment, and multidisciplinary decision-making are essential for optimal outcomes. Learning points:


  • Methimazole-Induced Pancytopenia in a Patient with Graves' Disease: A Case Report and Literature Review

    by Marcio José Concepcion-Zavaleta, Juan Eduardo Quiroz-Aldave, Katia Eugenia Rivera Fabián, Sofia Pilar Ildefonso-Najarro, Karol Magdalena Moscol Chavez, Luis Alberto Concepcion-Urteaga, Jose Paz-Ibarra

    Introduction: Methimazole is an antithyroid drug known to cause hematological toxicity, including agranulocytosis and, very rarely, pancytopenia. We herein present a case of a patient with Graves' Disease (GD) who developed methimazole-induced pancytopenia. Case Report: A 53-year-old Peruvian woman with GD, initially treated with methimazole 20 mg BID, experienced odynophagia, fever, and malaise after 37 days of treatment. The initial diagnosis was agranulocytosis, leading to the discontinuation of methimazole and initiation of antibiotics. Due to persistent neutropenia, a Granulocyte Colony-stimulating Factor (G-CSF) was administered. Eight days later, she developed pancytopenia and was managed with hematopoietic agents and platelet transfusions. The patient recovered with normalization of the blood count, eliminating the need for Bone Marrow (BM) examination. Radioiodine therapy was chosen as the definitive treatment, resulting in hypothyroidism. Currently, the patient is thyroidal and hematologically stable. Conclusion: Methimazole-induced pancytopenia is a rare and serious complication; however, with appropriate treatment, complete recovery can be achieved.


  • Open Access

    The diagnosis of LADA diabetes in a low-resource country: A Peruvian case series

    by Juan Eduardo Quiroz-Aldave, María del Carmen Durand-Vásquez, Sofía Pilar Ildefonso-Najarro, Elman Rolando Gamarra-Osorio, Susan Luciana Puelles-León, Cyntia Mileini Quesquén-García, Luis Alberto Concepción-Urteaga, José Paz-Ibarra, Elena Alvarado-León, Edi William Aguilar Urbina, et al.

    Introduction: Diabetes mellitus (DM) is a global public health concern, affecting 10% of adults. Among its variants, latent autoimmune diabetes in adults (LADA) accounts for 3% to 11% of cases. Limited awareness and high testing costs contribute to misdiagnosis and inadequate treatment, increasing the risk of chronic complications. Design: A cases series. Methods: Fifteen Peruvian patients with LADA were studied to describe their clinical presentation, diagnosis, and treatment. Results: The average age was 36.2 years, with a mean disease duration of 5.6 years. All patients presented with acute symptoms, and their mean body mass index at diagnosis was 23.3 kg/m². Glycemic control was achieved with an average daily insulin dose of 0.96 IU/kg. None of the patients had access to capillary glucose self-monitoring or continuous glucose monitoring, as all were living in poverty or extreme poverty. Conclusions: LADA is an uncommon form of early-onset DM whose diagnosis and treatment in resource-limited countries are impacted by socioeconomic conditions. Therefore, we propose a clinical algorithm for managing this condition in low-resource settings.